MSFrontier

Negative and mixed results

Trials of medicines meant to change the course of MS that did not meet their main goal, or gave mixed results. A failed trial can rule out a medicine, a dose or a group of people without ruling out the idea behind it.
Negative and mixed trial results in Hypotheses →
  • CUPID

    dronabinol · Phase 3 · Progressive MS · Did not meet its main goal

    From the abstract

    145 patients in the dronabinol group had EDSS score progression (0·24 first progression events per patient-year; crude rate) compared with 73 in the placebo group (0·23 first progression events per patient-year; crude rate); HR for prespecified primary analysis was 0·92 (95% CI 0·68-1·23; p=0·57).
  • Glatiramer acetate, phase 3

    glatiramer acetate, interferon beta-1a · Phase 3 · Relapsing MS · Did not meet its main goal

    From the abstract

    MRI disease activity-free status did not differ (p = 0.09).
  • Interferon beta-1a, phase 4

    interferon beta-1a · Phase 4 · Relapsing MS · Did not meet its main goal

  • Briakinumab, phase 2

    briakinumab · Phase 2 · MS (type not specified) · Mixed result

    From the abstract

    At week 24, gadolinium-enhanced lesions were statistically significantly reduced with ABT-874 200 mg EOW vs. placebo (mean number [SD]: 5.4 [8.1] vs. 7.6 [14.4], p = 0.003), but not with ABT-874 200 mg EW (6.8 [11.3], p = 0.134).
  • OLYMPUS

    rituximab · Phase 2 / Phase 3 · Progressive MS · Did not meet its main goal

  • STAYCIS

    atorvastatin · Phase 2 · Early (CIS/RIS) · Did not meet its main goal

  • Interferon beta-1b, phase 3

    interferon beta-1b · Phase 3 · Relapsing MS · Did not meet its main goal

    From the abstract

    We found no differences in relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume among treatment groups.
  • Glatiramer acetate, phase 3

    glatiramer acetate · Phase 3 · Relapsing MS · Did not meet its main goal

    From the abstract

    Combination IFN+GA was not superior to the better of the single agents (GA) in risk of relapse.
  • PRIVIG

    human immunoglobulin g · Phase 2 · Relapsing MS · Did not meet its main goal

  • PROMESS

    cyclophosphamide anhydrous · Phase 3 · Progressive MS · Did not meet its main goal

    From the abstract

    Primary endpoint: the hazard ratio for EDSS deterioration in the CPM in comparison with the MP group was 0.61 [95% CI: 0·31-1·22](p = 0·16).

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error